与未接种者相比,接种1剂或2剂JYNNEOS疫苗后猴痘风险降低——美国43个司法管辖区,2022年7月31日至10月1日
分析美国43个司法管辖区2022年7月31日至10月1日18-49岁男性中9544例猴痘报告病例,按疫苗接种状态比较发病率。未接种者猴痘发病率是仅接种1剂JYNNEOS疫苗≥14天者的7.4倍(95%CI=6.0-9.1),是接种第2剂≥14天者的9.6倍(95%CI=6.9-13.2)。有接种资格者应完成2剂系列以优化保护强度。
要点
- 未接种者猴痘发病率是仅接种1剂JYNNEOS疫苗≥14天者的7.4倍(95%CI=6.0-9.1)。
- 未接种者猴痘发病率是接种第2剂JYNNEOS疫苗≥14天者的9.6倍(95%CI=6.9-13.2)。
- 有猴痘疫苗接种资格者应完成2剂系列以优化保护强度。
核心结论
- 本报告提供额外数据提示JYNNEOS疫苗可预防猴痘,无论皮内或皮下接种;保护的程度和持久性仍不清楚。
- 有猴痘疫苗接种资格者应接种完整的2剂系列以优化保护强度。
研究设计与样本
- 分析美国43个司法管辖区2022年7月31日至10月1日18-49岁男性中9544例猴痘报告病例,按疫苗接种状态比较发病率。
主要发现
- 研究期间,未接种者猴痘发病率(每10万风险人群病例数)是仅接种1剂JYNNEOS疫苗≥14天者的7.4倍(95%CI=6.0-9.1)。
- 未接种者猴痘发病率是接种第2剂JYNNEOS疫苗≥14天者的9.6倍(95%CI=6.9-13.2)。
- 接种疫苗的猴痘病例中,第1剂皮下与皮内接种途径的观察分布与预期分布无差异。
关键数值与推荐
- JYNNEOS疫苗(改良安卡拉痘苗疫苗,Bavarian Nordic)皮下接种为2剂系列(每剂0.5 mL,间隔4周),2019年获FDA批准用于预防天花和猴痘。
- 2022年8月9日FDA紧急使用授权批准皮内接种每剂0.1 mL。
- 2022年9月4日至10月1日,美国共有205504人接种JYNNEOS疫苗第2剂。
临床怎么用
- 有猴痘疫苗接种资格者应接种完整的2剂系列以优化保护强度。
局限性
- JYNNEOS疫苗对猴痘保护的程度和持久性仍不清楚。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
As of October 28, 2022, a total of 28,244* monkeypox (mpox) cases have been reported in the United States during an outbreak that has disproportionately affected gay, bisexual, and other men who have sex with men (MSM) (1). JYNNEOS vaccine (Modified Vaccinia Ankara vaccine, Bavarian Nordic), administered subcutaneously as a 2-dose (0.5 mL per dose) series (with doses administered 4 weeks apart), was approved by the Food and Drug Administration (FDA) in 2019 to prevent smallpox and mpox disease (2); an FDA Emergency Use Authorization issued on August 9, 2022, authorized intradermal administration of 0.1 mL per dose, increasing the number of persons who could be vaccinated with the available vaccine supply† (3). A previous comparison of mpox incidence during July 31-September 3, 2022, among unvaccinated, but vaccine-eligible men aged 18-49 years and those who had received ≥1 JYNNEOS vaccine dose in 32 U.S. jurisdictions, found that incidence among unvaccinated persons was 14 times that among vaccinated persons (95% CI = 5.0-41.0) (4). During September 4-October 1, 2022, a total of 205,504 persons received JYNNEOS vaccine dose 2 in the United States.§ To further examine mpox incidence among persons who were unvaccinated and those who had received either 1 or 2 JYNNEOS doses, investigators analyzed data on 9,544 reported mpox cases among men¶ aged 18-49 years during July 31-October 1, 2022, from 43 U.S. jurisdictions,** by vaccination status. During this study period, mpox incidence (cases per 100,000 population at risk) among unvaccinated persons was 7.4 (95% CI = 6.0-9.1) times that among persons who received only 1 dose of JYNNEOS vaccine ≥14 days earlier and 9.6 (95% CI = 6.9-13.2) times that among persons who received dose 2 ≥14 days earlier. The observed distribution of subcutaneous and intradermal routes of administration of dose 1 among vaccinated persons with mpox was not different from the expected distribution. This report provides additional data suggesting JYNNEOS vaccine provides protection against mpox, irrespective of whether the vaccine is administered intradermally or subcutaneously. The degree and durability of such protection remains unclear. Persons eligible for mpox vaccination should receive the complete 2-dose series to optimize strength of protection†† (5).
引用
- Payne AB, Ray LC, Cole MM, et al. Reduced Risk for Mpox After Receipt of 1 or 2 Doses of JYNNEOS Vaccine Compared with Risk Among Unvaccinated Persons - 43 U.S. Jurisdictions, July 31-October 1, 2022. MMWR Morb Mortal Wkly Rep. 2022. PMID: 36480479. doi:10.15585/mmwr.mm7149a5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。